Welcome to our dedicated page for Atossa Therapeutics news (Ticker: ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics stock.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company whose news flow centers on the development of its lead investigational therapy, (Z)-Endoxifen. Company announcements frequently cover progress in breast cancer programs, regulatory interactions, intellectual property developments, and emerging opportunities in other serious diseases.
Investors following ATOS news can expect regular updates on clinical trials involving (Z)-Endoxifen, including studies in metastatic ER+/HER2- breast cancer, neoadjuvant treatment for premenopausal ER+/HER2- patients, breast cancer risk reduction strategies focused on mammographic breast density, and participation in the RECAST DCIS platform trial for hormone receptor–positive ductal carcinoma in situ. These releases often summarize trial design, early findings, and the potential implications for future registration strategies.
Atossa’s news also highlights regulatory milestones, such as FDA Type C meetings, Investigational New Drug (IND) submissions, and “Study May Proceed” letters. Additional coverage includes the FDA’s Rare Pediatric Disease designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy, as well as AI-enabled research collaborations identifying new oncology indications like glioblastoma.
Another recurring theme in ATOS news is the company’s intellectual property position, including newly issued patents for enteric oral (Z)-Endoxifen formulations and methods of use in hormone-dependent breast disorders and estrogen-related conditions. Corporate updates, such as financial results, leadership appointments, and Nasdaq listing communications, provide context on Atossa’s operational and strategic direction.
By monitoring this news page, readers can review a chronological record of Atossa’s clinical, regulatory, scientific, and corporate announcements related to (Z)-Endoxifen and the company’s broader oncology and rare disease programs.
A recent study by Dr. Steven Quay, head of COVID-19 therapeutic programs at Atossa Therapeutics (NASDAQ: ATOS), published on Zenodo, suggests that the SARS-CoV-2 pandemic may have originated at the PLA Hospital in Wuhan, China. The research indicates that early patient records dated back to December 10, 2019, prior to official announcements. The study highlights that the hospital is near the Wuhan Institute of Virology, where genetic links to bat coronaviruses exist. Additionally, it identifies the Wuhan Metro Line 2 as a significant conduit for virus transmission.
Atossa Therapeutics (Nasdaq: ATOS) has completed enrollment in its Phase 1 clinical study of AT-301, a nasal spray drug candidate aimed at treating COVID-19. This is a significant milestone as the ongoing pandemic intensifies. The study, conducted in Australia with 32 healthy adults, assesses the safety and tolerability of AT-301. Atossa plans to report preliminary results soon and is also seeking partners for co-development of AT-301 while preparing for a Phase 2 study in the first half of 2021.
Atossa Therapeutics (Nasdaq: ATOS) is set to present on October 13, 2020, at a Tribe Public Zoom Webinar during Breast Cancer Awareness Month. CEO Dr. Steven Quay and CFO Kyle Guse will lead a discussion titled “Atossa Therapeutics: Tackling our Greatest Health Challenges – COVID-19 and Breast Cancer”. The event, beginning at 8 AM PT/11 AM ET, will include a Q&A on Atossa’s breast cancer initiatives and COVID-19 treatment programs, particularly the nasal spray therapy AT-301. Registration for the event is complimentary but limited.
On October 2, 2020, Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), gifted 50 copies of his book, "Stay Safe: a Physician's Guide to Survive Coronavirus," to the White House after President Trump and the First Lady tested positive for COVID-19. The book provides essential advice on preventing and managing COVID-19, aiming to aid recovery. Profits from the book sales are donated to a military veterans group assisting COVID-19 impacted communities. Dr. Quay's extensive experience in drug development underpins the book's insights.
Atossa Therapeutics (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced that CEO Dr. Steven Quay and CFO Kyle Guse will present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit. The event is being held virtually from September 21-23, 2020, with Atossa's presentation scheduled for September 22 at 9:10 AM ET. The company focuses on innovative medicines for breast cancer and COVID-19, and interested participants can register via email.
Atossa Therapeutics (Nasdaq: ATOS) announced a positive interim safety assessment from the second cohort in its Phase 1 clinical study of AT-301, a nasal spray for COVID-19. The safety committee's favorable review allows the company to proceed with the next cohort. The study aims to evaluate AT-301's safety and tolerability among healthy adults. Atossa plans to develop AT-301 for home use to help patients recover faster from early COVID-19 symptoms, targeting high-risk communities and healthcare workers.
Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), has released a book titled "Stay Safe: A Physician's Guide to Survive Coronavirus", which has reached number one on five Amazon New Release Bestseller lists in various medical categories. The book offers vital information on navigating the pandemic, including tips on school safety and flu vaccinations. With over 28 million confirmed COVID-19 cases globally, Dr. Quay emphasizes the importance of sharing science-backed insights during this critical time, especially amidst ongoing vaccine trials.
Dr. Steven Quay, CEO of Atossa Therapeutics (NASDAQ: ATOS), shares effective tips for enhancing cloth Covid-19 masks, featured in FOX 26 Houston and his new book, "Stay Safe: A Physician's Guide to Survive Coronavirus." This guide compiles science-backed insights to alleviate pandemic-related concerns, offering practical solutions for better protection. Quay's innovative "salt spray" method, made from salt, water, and dish soap, enhances mask effectiveness. His book is available on Amazon, providing dozens of lifesaving recommendations for Covid-19 safety.
Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported a positive interim safety assessment from the first cohort of its Phase 1 clinical study for AT-301, a nasal spray drug candidate aimed at treating COVID-19. The study involved 8 healthy participants who received either a placebo or an active dose, leading to a favorable safety review. This milestone allows the company to proceed with patient enrollment for higher doses and repeated dose cohorts. The Phase 1 study, taking place in Australia, focuses on the safety and tolerability of AT-301, thus paving the way for further efficacy investigations.
Atossa Therapeutics (Nasdaq: ATOS) announced that CEO Dr. Steven Quay will present at the LD Micro 500 virtual conference on September 4, 2020, at 9:00 AM ET. This presentation will be followed by a live Q&A session for registered investors and attendees. Additionally, Dr. Quay is available for one-on-one virtual meetings from September 1-4, 2020. Atossa focuses on developing innovative medicines for unmet medical needs, particularly in breast cancer and COVID-19. For further details, visit www.atossatherapeutics.com.